explore -WSS

explore

author：fashion 2025-10-01 22:59:35 - browse：9

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system.

The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Prior authorization will have to move faster under new Biden rule

WSS

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Eli Lilly, Pfizer, and others want in on the online prescription market

Prior authorization will have to move faster under new Biden rule

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Readout LOUD podcast: possible new ALS drug, artificial wombs

Francis Collins on trust in science and how Covid communications failed

Wikipedia

explore

focus

Hepatitis C has a cure — but many Americans still lack access to it

Think you might have Covid

ChatGPT in medicine: STAT answers readers' burning questions

Humana cuts profit projections as Medicare Advantage costs soar

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Prior authorization will have to move faster under new Biden rule

How to save PrEP access — and even expand it

Humana cuts profit projections as Medicare Advantage costs soar

Activists slam private health insurers over coverage restrictions

Senate HELP committee spars over health care workforce policies

hotspot

NIH director takes cautious approach to Biden drug pricing priority

New brain studies show LSD's effects on the brain in full color

The surgeon had a dilemma only a Nazi medical text could resolve

How Vertex's cystic fibrosis drug is changing patients' lives

Dewpoint Therapeutics lays off staff after losing partnerships

Microbiome research is starting to find links to chronic diseases

leisure time

hotspot

focus

knowledge